• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

李-佛美尼氏症探索联合协会数据协调中心:为罕见病症的合作性国际癌症流行病学研究构建一个互动式网络资源。

Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition.

机构信息

Center for Medical Genetics and Genomics, University of Pittsburgh, Pittsburgh, Pennsylvania.

City of Hope National Medical Center, Duarte, California.

出版信息

Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):927-935. doi: 10.1158/1055-9965.EPI-19-1113. Epub 2020 Mar 10.

DOI:10.1158/1055-9965.EPI-19-1113
PMID:32156722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7196512/
Abstract

BACKGROUND

The success of multisite collaborative research relies on effective data collection, harmonization, and aggregation strategies. Data Coordination Centers (DCC) serve to facilitate the implementation of these strategies. The utility of a DCC can be particularly relevant for research on rare diseases where collaboration from multiple sites to amass large aggregate datasets is essential. However, approaches to building a DCC have been scarcely documented.

METHODS

The Li-Fraumeni Exploration (LiFE) Consortium's DCC was created using multiple open source packages, including LAM/G Application (Linux, Apache, MySQL, Grails), Extraction-Transformation-Loading (ETL) Pentaho Data Integration Tool, and the Saiku-Mondrian client. This document serves as a resource for building a rare disease DCC for multi-institutional collaborative research.

RESULTS

The primary scientific and technological objective to create an online central repository into which data from all participating sites could be deposited, harmonized, aggregated, disseminated, and analyzed was completed. The cohort now include 2,193 participants from six contributing sites, including 1,354 individuals from families with a pathogenic or likely variant in . Data on cancer diagnoses are also available. Challenges and lessons learned are summarized.

CONCLUSIONS

The methods leveraged mitigate challenges associated with successfully developing a DCC's technical infrastructure, data harmonization efforts, communications, and software development and applications.

IMPACT

These methods can serve as a framework in establishing other collaborative research efforts. Data from the consortium will serve as a great resource for collaborative research to improve knowledge on, and the ability to care for, individuals and families with Li-Fraumeni syndrome.

摘要

背景

多中心合作研究的成功依赖于有效的数据收集、协调和聚合策略。数据协调中心(DCC)有助于实施这些策略。DCC 的实用性对于罕见病研究尤为重要,因为需要从多个站点合作汇集大型聚合数据集。然而,建立 DCC 的方法几乎没有被记录下来。

方法

Li-Fraumeni 探索(LiFE)联盟的 DCC 使用了多个开源软件包,包括 LAM/G 应用程序(Linux、Apache、MySQL、Grails)、提取-转换-加载(ETL)Pentaho 数据集成工具和 Saiku-Mondrian 客户端。本文档为建立用于多机构合作研究的罕见病 DCC 提供了资源。

结果

创建一个在线中央存储库,将所有参与站点的数据存入其中,进行协调、聚合、传播和分析的主要科学和技术目标已经完成。该队列现在包括来自六个合作站点的 2193 名参与者,其中 1354 名来自携带致病性或可能变异的家族。癌症诊断数据也可用。总结了挑战和经验教训。

结论

所利用的方法减轻了成功开发 DCC 的技术基础设施、数据协调工作、通信以及软件开发和应用相关的挑战。

影响

这些方法可以作为建立其他合作研究的框架。该联盟的数据将成为合作研究的宝贵资源,以提高对 Li-Fraumeni 综合征患者和家庭的认识,并提高治疗能力。

相似文献

1
Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition.李-佛美尼氏症探索联合协会数据协调中心:为罕见病症的合作性国际癌症流行病学研究构建一个互动式网络资源。
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):927-935. doi: 10.1158/1055-9965.EPI-19-1113. Epub 2020 Mar 10.
2
Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.携致病性或疑似致病性种系 TP53 变异个体的癌症发病情况、模式及基因型-表型相关性:一项观察性队列研究。
Lancet Oncol. 2021 Dec;22(12):1787-1798. doi: 10.1016/S1470-2045(21)00580-5. Epub 2021 Nov 12.
3
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.基于国际胚系 TP53 变异数据集中的 Li-Fraumeni 谱分析:国际癌症研究机构 TP53 数据库分析。
JAMA Oncol. 2021 Dec 1;7(12):1800-1805. doi: 10.1001/jamaoncol.2021.4398.
4
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.巴西个体中 TP53 p.R337H 突变的 Li-Fraumeni 综合征/Li-Fraumeni 样综合征的临床谱。
J Steroid Biochem Mol Biol. 2019 Jun;190:250-255. doi: 10.1016/j.jsbmb.2019.04.011. Epub 2019 Apr 8.
5
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.美国国立癌症研究所李-弗劳梅尼综合征队列中TP53突变携带者首次患癌及后续患癌风险
Cancer. 2016 Dec 1;122(23):3673-3681. doi: 10.1002/cncr.30248. Epub 2016 Aug 6.
6
Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.TP53基因种系突变携带者的全身磁共振成像(WB-MRI)和脑部MRI基线监测:来自李-弗劳梅尼综合征教育与早期检测(LEAD)诊所的经验。
Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.
7
Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.Li-Fraumeni 综合征家系中首次和二次原发癌诊断的穿透率估计:单机构视角。
Cancer Res. 2020 Jan 15;80(2):347-353. doi: 10.1158/0008-5472.CAN-19-0725. Epub 2019 Nov 12.
8
Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.胚系 TP53 突变、MDM2 SNP309 及性别对 Li-Fraumeni 综合征家系癌症风险的联合作用。
Hum Genet. 2011 Jun;129(6):663-73. doi: 10.1007/s00439-011-0957-1. Epub 2011 Feb 9.
9
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.胚系 TP53 突变携带者 Li-Fraumeni 综合征的生化和影像学监测:前瞻性观察研究的 11 年随访。
Lancet Oncol. 2016 Sep;17(9):1295-305. doi: 10.1016/S1470-2045(16)30249-2. Epub 2016 Aug 5.
10
Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.巴西南部儿童癌症患者中李-佛美尼综合征和李-佛美尼样综合征。
Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.

引用本文的文献

1
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.Li Fraumeni 综合征成人接受每年 MRI 监测的二甲双胍癌症精准预防试验(MILI):一项随机对照试验方案。
Trials. 2024 Feb 3;25(1):103. doi: 10.1186/s13063-024-07929-w.
2
Lessons learned and recommendations for data coordination in collaborative research: The CSER consortium experience.协作研究中数据协调的经验教训与建议:CSER 联盟的经验
HGG Adv. 2022 May 20;3(3):100120. doi: 10.1016/j.xhgg.2022.100120. eCollection 2022 Jul 14.
3
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.多组织分析揭示的克隆性造血和嵌合体与 TP53 基因的结构状态。
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1621-1629. doi: 10.1158/1055-9965.EPI-21-1296.
4
Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body.李-佛美尼综合征患者家庭所承受的身体风险:就像电流穿过我的身体。
Soc Sci Med. 2022 May;301:114905. doi: 10.1016/j.socscimed.2022.114905. Epub 2022 Mar 17.
5
Inherited TP53 Variants and Risk of Prostate Cancer.遗传 TP53 变异与前列腺癌风险。
Eur Urol. 2022 Mar;81(3):243-250. doi: 10.1016/j.eururo.2021.10.036. Epub 2021 Dec 1.

本文引用的文献

1
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.基于全身磁共振成像的 Li-Fraumeni 综合征的基线监测:一项荟萃分析。
JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968.
2
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.美国国立癌症研究所李-弗劳梅尼综合征队列中TP53突变携带者首次患癌及后续患癌风险
Cancer. 2016 Dec 1;122(23):3673-3681. doi: 10.1002/cncr.30248. Epub 2016 Aug 6.
3
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.重新审视携 TP53 突变者的李-佛美尼综合征。
J Clin Oncol. 2015 Jul 20;33(21):2345-52. doi: 10.1200/JCO.2014.59.5728. Epub 2015 May 26.
4
Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.种系TP53突变与李-佛美尼综合征的变化态势
Hum Mutat. 2014 Jun;35(6):654-62. doi: 10.1002/humu.22559.
5
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.李-弗劳梅尼综合征:临床研究研讨会报告及研究联盟的创建
Cancer Genet. 2012 Oct;205(10):479-87. doi: 10.1016/j.cancergen.2012.06.008. Epub 2012 Aug 29.
6
Routine TP53 testing for breast cancer under age 30: ready for prime time?30 岁以下乳腺癌患者的常规 TP53 检测:是否已准备好进入黄金时代?
Fam Cancer. 2012 Dec;11(4):607-13. doi: 10.1007/s10689-012-9557-z.
7
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.携带有胚系 TP53 突变的女性的乳腺癌表型:Li-Fraumeni 综合征联盟的研究成果。
Breast Cancer Res Treat. 2012 Jun;133(3):1125-30. doi: 10.1007/s10549-012-1993-9. Epub 2012 Mar 4.
8
Informatics and data quality at collaborative multicenter Breast and Colon Cancer Family Registries.协作式多中心乳腺癌和结肠癌家族登记处的信息学和数据质量。
J Am Med Inform Assoc. 2012 Jun;19(e1):e125-8. doi: 10.1136/amiajnl-2011-000546. Epub 2012 Feb 9.
9
Coordinating centers in cancer epidemiology research: the Asia Cohort Consortium coordinating center.癌症流行病学研究协调中心:亚洲队列联盟协调中心。
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2115-9. doi: 10.1158/1055-9965.EPI-11-0391. Epub 2011 Jul 29.
10
Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers.TP53 种系突变携带者队列研究中 TP53 PIN3 多态性对癌症风险的性别特异性影响。
Hum Genet. 2011 Dec;130(6):789-94. doi: 10.1007/s00439-011-1039-0. Epub 2011 Jun 19.